Specifically, in CLL, different works support the role of TGF-β pathway as a growth inhibitor of CLL cells [40], and recently, SMAD protein expression has been correlated with disease progression [29]. This evidence concerns the gene TGFB1 and B-cell chronic lymphocytic leukemia.